- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy in pediatric acute lymphoblastic leukemia
Authors
Keywords
-
Journal
CANCER AND METASTASIS REVIEWS
Volume 38, Issue 4, Pages 595-610
Publisher
Springer Science and Business Media LLC
Online
2019-12-07
DOI
10.1007/s10555-019-09834-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
- (2019) Mohamad Hamieh et al. NATURE
- Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)
- (2019) Georg Maschmeyer et al. LEUKEMIA
- Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia
- (2019) David T Teachey et al. LANCET ONCOLOGY
- Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance
- (2019) Megan R. Paul et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Fratricide-resistant CD1a-specific CAR T-cells for the treatment of cortical T-cell acute lymphoblastic leukemia
- (2019) Diego Sánchez-Martínez et al. BLOOD
- Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
- (2019) Anthony S. Stein et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Modulation of Target Antigen Density Improves CAR T Cell Functionality and Persistence
- (2019) Sneha Ramakrishna et al. CLINICAL CANCER RESEARCH
- Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
- (2019) Sara Ghorashian et al. NATURE MEDICINE
- Efficacy and Safety of CAR19/22 T-cell "Cocktail" Therapy in Patients with Refractory/ Relapsed B-Cell Malignancies
- (2019) Na Wang et al. BLOOD
- Treatment of testicular relapse of B-cell acute lymphoblastic leukemia with CD19-specific chimeric antigen receptor T cells
- (2019) Xiaojuan Chen et al. Clinical Lymphoma Myeloma & Leukemia
- Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy
- (2019) Rebecca A. Gardner et al. BLOOD
- Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16
- (2019) Sima Jeha et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial
- (2019) Theodore W Laetsch et al. LANCET ONCOLOGY
- Blinatumomab for MRD+B-ALL: the evidence strengthens
- (2018) Patrick Brown BLOOD
- Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
- (2018) Nicola Gökbuget et al. BLOOD
- False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy
- (2018) Theodore W. Laetsch et al. BLOOD
- Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
- (2018) Max S. Topp et al. BLOOD
- Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia
- (2018) Hagop M. Kantarjian et al. CANCER
- Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study
- (2018) Hagop Kantarjian et al. LANCET ONCOLOGY
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia
- (2018) Matthew J. Oberley et al. PEDIATRIC BLOOD & CANCER
- Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)
- (2018) Bianca D. Santomasso et al. Cancer Discovery
- Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia
- (2018) Elias Jabbour et al. JAMA Oncology
- Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia
- (2018) John K. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
- (2018) Deepa Bhojwani et al. LEUKEMIA
- The genetic basis and cell of origin of mixed phenotype acute leukaemia
- (2018) Thomas B. Alexander et al. NATURE
- Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
- (2018) Marco Ruella et al. NATURE MEDICINE
- Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
- (2018) Elena J. Orlando et al. NATURE MEDICINE
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage
- (2018) Elias Jabbour et al. CANCER
- What Can Cost-Effectiveness Analysis Tell Us About Chimeric Antigen Receptor T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia?
- (2018) Christopher R. Flowers et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
- (2018) Reith R Sarkar et al. JNCI-Journal of the National Cancer Institute
- Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
- (2018) Judith Feucht et al. NATURE MEDICINE
- Somatic and germline genomics in paediatric acute lymphoblastic leukaemia
- (2018) Ching-Hon Pui et al. Nature Reviews Clinical Oncology
- Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia
- (2018) Melanie D. Whittington et al. JAMA Pediatrics
- FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease
- (2018) Emily Y. Jen et al. CLINICAL CANCER RESEARCH
- Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
- (2017) Giovanni Martinelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
- (2017) J Duell et al. LEUKEMIA
- Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia
- (2017) C Rossig et al. LEUKEMIA
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
- (2017) Waseem Qasim et al. Science Translational Medicine
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
- (2017) Juliane Gust et al. Cancer Discovery
- Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study
- (2017) Hagop M Kantarjian et al. Lancet Haematology
- A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines
- (2017) Dina Schneider et al. Journal for ImmunoTherapy of Cancer
- Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
- (2016) Friederike Braig et al. BLOOD
- Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
- (2016) R. Gardner et al. BLOOD
- Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy
- (2016) V. G. Bhoj et al. BLOOD
- Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies
- (2016) M. Sabatino et al. BLOOD
- Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies
- (2016) Hagop M. Kantarjian et al. CANCER
- Liver Microvascular Injury and Thrombocytopenia of Antibody–Calicheamicin Conjugates in Cynomolgus Monkeys—Mechanism and Monitoring
- (2016) Magali Guffroy et al. CLINICAL CANCER RESEARCH
- Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
- (2016) Marco Ruella et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
- (2016) Arend von Stackelberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
- (2016) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy
- (2016) Ahmad Rayes et al. PEDIATRIC BLOOD & CANCER
- Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies
- (2016) Nathan Singh et al. Science Translational Medicine
- CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
- (2016) Elad Jacoby et al. Nature Communications
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
- (2016) D. T. Teachey et al. Cancer Discovery
- A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies
- (2015) M. Mamonkin et al. BLOOD
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
- (2015) S. L. Maude et al. BLOOD
- Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein
- (2015) H. Qin et al. BLOOD
- Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment
- (2015) G. Zugmaier et al. BLOOD
- FDA Approval: Blinatumomab
- (2015) D. Przepiorka et al. CLINICAL CANCER RESEARCH
- Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
- (2015) Ching-Hon Pui et al. JOURNAL OF CLINICAL ONCOLOGY
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
- (2015) E. Sotillo et al. Cancer Discovery
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
- (2013) D. T. Teachey et al. BLOOD
- Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
- (2013) Hagop Kantarjian et al. CANCER
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
- (2012) W. Haso et al. BLOOD
- Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
- (2012) M. Klinger et al. BLOOD
- Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
- (2012) M. S. Topp et al. BLOOD
- Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
- (2012) Hagop Kantarjian et al. LANCET ONCOLOGY
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
- (2011) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia
- (2010) Pier Paolo Piccaluga et al. LEUKEMIA & LYMPHOMA
- Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
- (2009) Ching-Hon Pui et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now